{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:32:41Z","timestamp":1771471961507,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10557-023-07498-1","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T10:02:38Z","timestamp":1691402558000},"page":"859-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iron Status Screening in Individuals with Heart Failure Before Initiating Sodium-Glucose Cotransporter 2 Inhibitor Therapy: Is It Necessary?"],"prefix":"10.1007","volume":"38","author":[{"given":"Ana","family":"Cirovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-9559","authenticated-orcid":false,"given":"Aleksandar","family":"Cirovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"issue":"7","key":"7498_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"M Packer","year":"2023","unstructured":"Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nature Reviews Cardiology. 2023;20(7):443\u201362.","journal-title":"Nature Reviews Cardiology"},{"issue":"7","key":"7498_CR2","doi-asserted-by":"publisher","first-page":"e22410","DOI":"10.1096\/fj.202200243R","volume":"36","author":"Z Yang","year":"2022","unstructured":"Yang Z, Li T, Xian J, et al. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2\u03b1 signaling pathway in arrhythmogenic cardiomyopathy. The FASEB Journal. 2022;36(7):e22410.","journal-title":"The FASEB Journal"},{"issue":"8","key":"7498_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, Hare GM, Connelly PW, et al. Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020;141(8):704\u20137.","journal-title":"Circulation"},{"issue":"1","key":"7498_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","volume":"11","author":"M Packer","year":"2023","unstructured":"Packer M. Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. JACC Heart Fail. 2023;11(1):106\u201314. https:\/\/doi.org\/10.1016\/j.jchf.2022.10.004.","journal-title":"JACC Heart Fail"},{"key":"7498_CR5","unstructured":"McDowell LA, Kudaravalli P, Sticco KL. Iron Overload. 2022 Apr 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.\u00a0"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07498-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07498-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07498-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:26:59Z","timestamp":1721788019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07498-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7498"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07498-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"28 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}